Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Tax Provisions (2023 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Tax Provisions for 3 consecutive years, with $150000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Tax Provisions fell 90.46% to $150000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.1 million, a 25.74% increase, with the full-year FY2025 number at -$2.1 million, up 25.74% from a year prior.
  • Tax Provisions was $150000.0 for Q4 2025 at Iovance Biotherapeutics, up from -$2.4 million in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $2.0 million in Q2 2025 to a low of -$2.4 million in Q3 2025.
  • A 3-year average of -$766090.9 and a median of -$1.4 million in 2024 define the central range for Tax Provisions.
  • Peak YoY movement for Tax Provisions: crashed 214.47% in 2024, then surged 230.0% in 2025.
  • Iovance Biotherapeutics' Tax Provisions stood at -$1.8 million in 2023, then soared by 188.36% to $1.6 million in 2024, then plummeted by 90.46% to $150000.0 in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Tax Provisions are $150000.0 (Q4 2025), -$2.4 million (Q3 2025), and $2.0 million (Q2 2025).